Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions

Polish Journal of Pathology

Volumn 63, Issue 1, 2012, Pages 58-64

  Mataraci, Emine Aycan ^a   Özgüven, Banu Yilmaz ^a   Kabukçuoǧlu, Fevziye ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Benign lesions; Cytokeratin 19; Galectin 3; HBME 1; Immunohistochemistry; Malignancy; Thyroid

Indexed keywords

CYTOKERATIN 19; GALECTIN 3; HBME 1 ANTIGEN; HBME-1 ANTIGEN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; HUMAN; METABOLISM; RETROSPECTIVE STUDY; THYROID DISEASE; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; HUMANS; KERATIN-19; RETROSPECTIVE STUDIES; THYROID DISEASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860179167     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Delellis RA, Williams ED. Tumours of the thyroid and parathyroid. In: The WHO classification of tumours of endocrine organs. Delellis RA, Lloyd RV, Heitz PU, Eng C (eds). IARC Press, Lyon 2004; 50-133.
2. Rosai J. Thyroid gland. In: Rosai J. Rosai and Ackerman's surgical pathology. 9th ed. Mosby Company 2004; 515-568.
3. Rosai J. Immunohistochemical markers of thyroid tumors significance and diagnostic applications. Tumori 2003; 89: 517-519.
4. Beesley MF, Mclaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002; 41: 236-243.
5. Cameron BR, Berean KW. Cytokeratin subtypes in thyroid tumors: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol 2003; 32: 319-322.
6. Miettinen M, Kovatich AJ. Keratin subset in papillary and follicular thyroid lesions. Virch Arch 1997; 431: 407-413.
7. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001; 14: 338-342.
8. Volante M, Bozzalla-Cassione F, Depompa R, et al. Galec tin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virch Arch 2004; 445: 183-188.
9. Saggiorato E, Cappia S, Giuli PD, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5152-5158.
10. Hermann ME, Livolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002; 126: 710-713.
11. Goossens A, Heimann R. CK19 is present in fetal thyroid tissue. Am J Clin Pathol 1989; 92: 654-658.
12. Lam KY, Lui MC, Lo CY. Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 2001; 27: 631-635.
13. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME-1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 700-708.
14. Barroeta JE, Baloch ZW, Lal P, et al. Diagnostic value of differential expression of CK19, galectin-3, HBME-1, erk, ret and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006; 17: 225-234.
15. Nakamura N, Erickson LA, Jin L, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol 2006; 17: 213-223.
16. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3 and HBME-1. Endocr Pathol 2003; 14: 55-60.
17. de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malinancy. Histopathology 2005; 47: 391-401.
18. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibro - nectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005; 18: 48-57.
19. Erickson LA, Lloyd RV. Utility of a panel of immunohistochemical markers in the diagnosis of follicular variant of papillary thyroid carcinoma. Adv Anat Pathol 2008; 15: 1.
20. Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27kip1 in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007; 22: 621-628.
21. Pisani T, Vecchione A, Giovagnoli MR. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma. Anticancer Res 2004; 24: 1111-1112.
22. Weinberger PM, Adam BL, Gourin CG, et al. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wntpathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133: 503-510.